Search

everythinglearnresearchcommunity

for

Search:↓

Blocking Hedgehog signaling offers new treatment options for advanced basal cell carcinoma.

GLI1 RNA CISH effectively identifies basal cell carcinoma but is less specific for benign follicular tumors.

New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.

A rare case showed basal cell carcinoma and leiomyosarcoma coexisting, needing careful diagnosis and treatment.

GLI and EGF signalling affect Basal Cell Carcinoma development and could be therapeutic targets.

Targeting the Smoothened receptor shows promise for treating certain cancers.

Targeted cancer therapies often cause skin side effects, needing dermatologist care.

UV photography can help identify people at higher risk for skin cancer, and male pattern baldness at age 45 is linked to a higher risk of certain skin cancers.

SOX4 is crucial for the development of melanoma.

The document concludes that individualized treatment for malignant epithelial tumors is necessary and more research on metastatic squamous cell carcinoma treatments is needed.

Targeted therapy for skin cancer is complex due to the role of the hedgehog pathway in both cancer and hair growth.

Scalp basal cell carcinoma may be more aggressive and harder to treat than other types, requiring special attention and further research.

The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.

YAP and TAZ proteins are necessary for the development of two types of skin cancer.

The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

Looking at tissue characteristics isn't reliable for telling apart basal cell carcinoma from certain benign skin tumors.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

The research suggests new treatments for skin cancer could target specific cell growth pathways.

The treatment was ineffective in humans.

Higher levels of nidogen1 and type IV collagen are found in basal cell carcinoma compared to normal skin.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

A woman with a new PTCH gene mutation has both Gorlin syndrome and severe hair loss.

A rare type of skin cancer on the scalp can be mistaken for hair loss, causing delayed diagnosis and severe damage.

Treatment restored normal sexual characteristics and blood condition in a patient with testicular cancer.

Basal cell carcinomas and squamous cell carcinomas have different gene activity patterns, suggesting unique treatment approaches.

Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.

Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.

A small group of slow-growing cells causes basal cell carcinoma to return after treatment.

Recognizing rare tumor combinations is crucial for accurate diagnosis and treatment.